RESUMEN
Objective To study the preventive effect of Omeprazole on post-endoscopic retrograde choledo-chopallcreatography(ERCP)-induced pancreatitis.Methods 126 patients were divided into two groups at random.One group received Omeprazole 20mg bid for two days.and the other group received placebo(Vitamine B).Blood was drawn in each group the day before,4 hours and 24 hours following ERCP for examination of amylase and hepa-torenal functions.Meanwhile Meanwhile the clinical manifestations of acute pancreatitis were also observed.Results Acute pancreatitis was clinically induced in 1.59% cases of placebo group,but none in the Omeprazole group.Hyperamy-lasemia occurred in 20.63%-7.93%in Omeprazole group at 4 hours and 24 hours after ERCP operation,while 30.16%.14.29%in placebo group;The incidence rate of acute pancreatitis following ERCP and hyperamylasemia 4 h after ERCP in omeprazole group were significantly lower than in placebo group(P<0.01,P<0.05).There were no significance differences in amylase 24 hours following ERCP between two groups(P>0.05).Concluslon Omeprazole can prevent the acute pancreatitis induced by ERCP to some extent.
RESUMEN
Objective To study on the efficacy of Octreotide prophylaxis of post ERCP pancreatitis (PEP) and hyperamylasemia. Methods The study was conducted in 12 digestive endoscopic units in China. Patients were randomized into two groups. Octreotide group: Octreotide (0. 3mg) were dissolved in 500 ml of 0.9% saline solution and administrated by continues intravenous infusion, beginning 1 hr before the endoscopic examination and continuing for 6 hr afterward, 0. 1 mg Octreotide were injected subcutaneously at 6h, 12h after the intravenous injection stopped. Control group was given a placebo (saline solution) intravenously without subcutaneous injection. Results A total of 961 patients were accepted in the study, 832 patients were enrolled in the final analysis, Octreotide group 414 cases, and control group 418 cases. The overall incidence of acute pancreatitis was 3.85% (32/832) .which includec 2.42% (10/414) in Octreotide group and 5. 26% (22/418) in control group (P =0. 046). Incidence of hyperamylasemia was 14. 9% (124/ 832) which included 12. 32% (51/414) in Octreotide group and 17. 46% (73/418) in controlled group (P = 0. 041). The two groups were matched in many basic aspects, such as sex, age, contrast agent, indication of ERCP, the times of visualization of pancreatic duct and bile duct, etc. There was no side effect associated with Octreotide found. Conclusion The results of this trial indicate that Octreotide can prevent post ERCP pancreatitis and hyperamylasemia.